Global ADHD Market Set for Further Growth, Expects GlobalData in Its Report Available at MarketPublishers.com07 Dec 2016 • by Natalie Aster
LONDON – The global attention deficit hyperactivity disorder (ADHD) marketplace is set to showcase growth in the upcoming years, though it is widely genericized. The growth will stem from the anticipated launch of assets from the ADHD pipeline that is heavily populated at the moment.
These products can boast clinical advantages that will encourage strong uptake. The expected increase in the number of drug-treated patients (in the adult age group in particular) will also encourage the growth.
The stimulant therapy has been dominating this space due to low availability of approved non-stimulant drugs.
However, there is no evidence of long-term safe use of stimulants, and this fact makes its counterparts increasingly popular across 7MM. With non-stimulant as well as stimulant therapies projected to reach the marketplace in the offing, the situation may change.
Novartis, Eli Lilly, Shire and Janssen are some of major players in this marketplace.
In-demand research report “ADHD - Global Drug Forecast and Market Analysis to 2024” worked out by GlobalData offers a comprehensive discussion of the worldwide ADHD market. The study provides a 360-degree overview of the disease. It focuses on its etiology and pathophysiology.
The report proceeds with a review of the disease’s classification, its symptoms and prognosis. The research study explores the disease background, looks at risk factors as well as comorbidities.
It investigates global trends and limelights the disease management. The research report sheds light on the competitive landscape and covers major products in detail. The study also scrutinizes unmet needs and existing opportunities.
It contains a detailed pipeline assessment. The report sheds light on current as well as future players. The research study examines key markets and gives future projections for the world’s marketplace.
Other Markets Explored by GlobalData Comprise:
- Glaucoma Surgery Devices in Japan
- Ophthalmic Diagnostic Equipment in Canada
- Multiparameter Patient Monitoring
- Hip Reconstruction
More studies by our partner are available at its page.